IS6967A - Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma - Google Patents
Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdómaInfo
- Publication number
- IS6967A IS6967A IS6967A IS6967A IS6967A IS 6967 A IS6967 A IS 6967A IS 6967 A IS6967 A IS 6967A IS 6967 A IS6967 A IS 6967A IS 6967 A IS6967 A IS 6967A
- Authority
- IS
- Iceland
- Prior art keywords
- diseases
- linked
- treatment
- dihydropyrimidine compounds
- new cyano
- Prior art date
Links
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical class C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995601P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009497 WO2002079149A2 (en) | 2001-03-29 | 2002-03-26 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS6967A true IS6967A (is) | 2003-09-24 |
Family
ID=23071059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6967A IS6967A (is) | 2001-03-29 | 2003-09-24 | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6809102B2 (is) |
| EP (1) | EP1373221A4 (is) |
| JP (1) | JP2005504725A (is) |
| KR (1) | KR20030086327A (is) |
| CN (1) | CN1507435A (is) |
| AR (1) | AR034585A1 (is) |
| BG (1) | BG108180A (is) |
| BR (1) | BR0208405A (is) |
| CA (1) | CA2442482A1 (is) |
| CZ (1) | CZ20032645A3 (is) |
| EE (1) | EE200300474A (is) |
| HR (1) | HRP20030875A2 (is) |
| HU (1) | HUP0400350A3 (is) |
| IL (1) | IL157441A0 (is) |
| IS (1) | IS6967A (is) |
| MX (1) | MXPA03008634A (is) |
| NO (1) | NO20034300L (is) |
| PE (1) | PE20021013A1 (is) |
| PL (1) | PL373759A1 (is) |
| RU (1) | RU2003130961A (is) |
| SK (1) | SK11062003A3 (is) |
| TW (1) | TWI228416B (is) |
| UY (1) | UY27232A1 (is) |
| WO (1) | WO2002079149A2 (is) |
| YU (1) | YU75803A (is) |
| ZA (2) | ZA200306648B (is) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| SI1847534T1 (sl) * | 2001-12-11 | 2011-10-28 | Kyowa Hakko Kirin Co Ltd | Tiadiazolinski derivati za zdravljenje raka |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| AU2004218080B2 (en) * | 2003-03-07 | 2008-01-03 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| CN1774428B (zh) * | 2003-04-18 | 2010-06-16 | 协和发酵麒麟株式会社 | M期驱动蛋白抑制剂 |
| US20070276017A1 (en) * | 2003-06-10 | 2007-11-29 | Chikara Murakata | Thiadiazoline Derivative |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| WO2005037799A1 (en) * | 2003-10-16 | 2005-04-28 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
| BRPI0514390A (pt) * | 2004-08-18 | 2008-06-10 | Astrazeneca Ab | enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
| US20080262049A1 (en) * | 2005-03-22 | 2008-10-23 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic Agent for Hematopoietic Tumor |
| KR20070113300A (ko) * | 2005-03-22 | 2007-11-28 | 교와 핫꼬 고교 가부시끼가이샤 | 고형종양 치료제 |
| JPWO2006137490A1 (ja) * | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | 再狭窄治療剤 |
| DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
| CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| EE9700209A (et) | 1994-11-16 | 1998-04-15 | Synaptic Pharmaceutical Corporation | Dihüdropürimidiinid ja nende kasutamine |
| WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| CA2253862A1 (en) | 1996-05-16 | 1997-11-20 | Wai C. Wong | Dihydropyrimidines and uses thereof |
| US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| CA2294349A1 (en) | 1997-06-18 | 1998-12-23 | Michael A. Patane | Alpha 1aadrenergic receptor antagonists |
| US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| EP1066527A2 (en) | 1998-04-01 | 2001-01-10 | Yale University | Method to identify modulators of survivin - tubulin interaction |
| US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
| AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| BR0015110A (pt) | 1999-10-27 | 2002-07-02 | Cytokinetics Inc | Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Withdrawn
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en not_active Ceased
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400350A3 (en) | 2005-06-28 |
| RU2003130961A (ru) | 2005-04-10 |
| HUP0400350A2 (hu) | 2005-01-28 |
| JP2005504725A (ja) | 2005-02-17 |
| CA2442482A1 (en) | 2002-10-10 |
| US20030008888A1 (en) | 2003-01-09 |
| YU75803A (sh) | 2006-05-25 |
| HRP20030875A2 (en) | 2004-08-31 |
| CZ20032645A3 (cs) | 2004-06-16 |
| PE20021013A1 (es) | 2002-11-10 |
| EE200300474A (et) | 2003-12-15 |
| UY27232A1 (es) | 2002-11-29 |
| NO20034300L (no) | 2003-11-07 |
| ZA200307320B (en) | 2004-12-20 |
| PL373759A1 (en) | 2005-09-05 |
| BR0208405A (pt) | 2004-03-30 |
| IL157441A0 (en) | 2004-03-28 |
| CN1507435A (zh) | 2004-06-23 |
| EP1373221A2 (en) | 2004-01-02 |
| WO2002079149A2 (en) | 2002-10-10 |
| US6809102B2 (en) | 2004-10-26 |
| NO20034300D0 (no) | 2003-09-26 |
| ZA200306648B (en) | 2004-11-26 |
| MXPA03008634A (es) | 2003-12-08 |
| BG108180A (en) | 2004-09-30 |
| SK11062003A3 (sk) | 2004-08-03 |
| EP1373221A4 (en) | 2004-09-29 |
| KR20030086327A (ko) | 2003-11-07 |
| AR034585A1 (es) | 2004-03-03 |
| TWI228416B (en) | 2005-03-01 |
| WO2002079149A3 (en) | 2003-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE05507B1 (et) | Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks | |
| DE60222671D1 (de) | Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen | |
| EE200300485A (et) | Tiohüdantoinid ja nende kasutamine diabeedi raviks | |
| IS6966A (is) | Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| EP1392818A4 (en) | FOR THE TREATMENT OF CANCER DISEASES IN HUMAN CERTAIN IMMUNE RECEPTOR | |
| PT1446122E (pt) | Utilizacao de flibanserina no tratamento de disturbios de desejo sexual | |
| IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
| DE60209486D1 (de) | Pyranoindazole und ihre verwendung in der glaukombehandlung | |
| DK1411064T3 (da) | Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer | |
| NO20041214L (no) | Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer | |
| ID27576A (id) | Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun | |
| DE60223576D1 (de) | Hautbehandlungszusammensetzung | |
| NO20033123D0 (no) | Terapeutisk hinnedannende sammensetning og behandlingsplan derav | |
| PL356784A1 (pl) | Substancja do zastosowania w leczeniu łuszczycy | |
| EE200400074A (et) | Koostised ning nende kasutamine proliferatiivsetehaiguste raviks | |
| EE200300328A (et) | IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks | |
| ITMI20010957A0 (it) | Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche | |
| NO20052699D0 (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
| NO20040659L (no) | Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom | |
| DK1496918T3 (da) | Anvendelse af natriummetaarsenit til behandling af tumorer | |
| IL162941A0 (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
| GB0119025D0 (en) | Compounds and their therapeutic use | |
| EE200300454A (et) | Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine | |
| PT1381620E (pt) | Dissacaridos hipersulfatados e metodos de utilizacao dos mesmos para o tratamento de inflamacoes |